Publications by authors named "M Nikiforova"
Context: BRAF V600E mutation is the most common genetic driver of papillary thyroid cancer (PTC), where it is found with various allele frequency (AF), reflecting the proportion of cells carrying the mutant and wild-type gene alleles.
Objective: To determine whether BRAF V600E AF can improve prognostication and inform initial surgical management of PTC.
Design: Retrospective cohort study (2016-2019).
Article Synopsis
- Molecular studies indicate that ALT is a crucial prognostic marker for shorter relapse-free survival (RFS) in pancreatic neuroendocrine tumors (PanNETs) and other neoplasms.
- The development of a new chromogenic ALT assay (ALT-CISH) was initiated to address clinical limitations of the traditional fluorescence in situ hybridization (FISH) method, showing a 100% agreement with FISH results in validating that ALT is present in 31% of primary PanNETs.
- The study demonstrated that ALT status is significantly associated with poorer RFS in both PanNET and leiomyosarcoma (LMS) patients, with ALT being an independent prognostic factor
Article Synopsis
- Ionogels were created by mixing Aerosil A380 with varying amounts (16.3 to 79.9 mol %) of a specific ionic liquid, 1-methyl-3-octyl-imidazolium tetrafluoroborate (OMIM BF).
- Evidence of changes in the ionic liquid's behavior was observed through NMR and IR spectroscopy, indicating that the liquid was confined within the silica structure, which also affected its decomposition temperature.
- Structural analysis revealed that the ionic liquid filled different pore sizes in the Aerosil, with notable increases in size correlations in higher IL content; this suggests that altering IL concentrations can modulate the material's properties effectively.
BRAFK601E is an uncommon mutation typically found in encapsulated follicular-patterned thyroid tumors. Previous studies on BRAFK601E-positive thyroid tumors were conducted before the implementation of the non-invasive follicular neoplasm with papillary-like nuclear features (NIFTP) diagnosis. This study aimed to characterize BRAFK601E-positive tumors and evaluate changes in the diagnosis and management of these patients after the introduction of NIFTP.
View Article and Find Full Text PDFArticle Synopsis
- The study evaluates how molecular testing can help determine the need for surgery in patients with differentiated thyroid carcinoma (DTC) sizes ranging from 1 to 4 cm and its association with disease recurrence.
- Among the analyzed patients, only 3.8% experienced recurrence, with no significant association found between recurrence and preoperative variables like tumor size, age, or sex.
- Molecular risk groups showed that intermediate risk tumors between 2.1-4 cm had a higher recurrence rate (11.3%) compared to smaller tumors (5.8%), indicating that size and molecular testing are important considerations for treatment decisions.